Biodesix Inc
NASDAQ:BDSX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biodesix Inc
Cash & Cash Equivalents
Biodesix Inc
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Biodesix Inc
NASDAQ:BDSX
|
Cash & Cash Equivalents
$19m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Quest Diagnostics Inc
NYSE:DGX
|
Cash & Cash Equivalents
$393m
|
CAGR 3-Years
31%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
12%
|
|
|
CVS Health Corp
NYSE:CVS
|
Cash & Cash Equivalents
$8.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
1%
|
CAGR 10-Years
13%
|
|
|
Cigna Corp
NYSE:CI
|
Cash & Cash Equivalents
$7.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
15%
|
|
|
Laboratory Corporation of America Holdings
NYSE:LH
|
Cash & Cash Equivalents
$532.3m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
-3%
|
|
|
Guardant Health Inc
NASDAQ:GH
|
Cash & Cash Equivalents
$378.2m
|
CAGR 3-Years
39%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
N/A
|
|
Biodesix Inc
Glance View
Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.
See Also
What is Biodesix Inc's Cash & Cash Equivalents?
Cash & Cash Equivalents
19m
USD
Based on the financial report for Dec 31, 2025, Biodesix Inc's Cash & Cash Equivalents amounts to 19m USD.
What is Biodesix Inc's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-21%
Over the last year, the Cash & Cash Equivalents growth was -28%. The average annual Cash & Cash Equivalents growth rates for Biodesix Inc have been -24% over the past three years , -21% over the past five years .
